54.55
—
Close of 5 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vilin Bio Med
Its shares trade on NSE under the ticker VILINBIO.NS. It has been listed since 30 June 2023. In the fiscal year to 31 March 2022, it reported revenue of ₹112.1m and net income of ₹335,000. At that date it held total assets of ₹135.6m and shareholders' equity of ₹74.0m.
Vilin Bio Med Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2023-06-30. Vilin Bio Med Limited is an India-based company. The firm is engaged in the domestic business of manufacturing pharmaceutical products. Its product categories include solid oral dosage forms (beta and non-beta-lactam), oral liquids, external preparations, and dry powders. Its products include Cefixime, Azithromycin, Sulmtmicilline, Aceclofenac, Citicolin Sodium, Metformine, Pregabaline, Gabapentin, Diclofenac Sodium, Thiocolchicoside, Linseed Oil, Menthol, and Methyl Salcilate, among others. Its external preparations offer ointments along with similar products like creams, lotions, gels, and pates in certain formulations primarily designed to be applied to the skin. Its beta-lactam products are a group of medicines that are used to treat infections caused by some germs (bacteria and certain parasites). Its non-beta-lactam tablets and capsule products are generally used for general diseases like colds, flu, fever, anti-gastrological, antimalaria, and several other viral diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jun 2023
- Website
- vilinbiomed.co.in ↗
Leadership
Pay as last reported
- Mr. Hari AvulaChief Financial Officer
- Mr. Madhusudan ReddyManaging Director, Executive Director, since 2024
- Mr. Viswa SadhanalaWhole-Time Director, since 2021
- Ms. Prasanna VennaWhole-Time Director, since 2025
- Mr. Dhruv TodiCompany Secretary
- Mr. Veeraiah KollaNon-Executive Independent Director
- Mr. Girish MukteviNon-Executive Independent Director
- Mr. Sasikanth ParitalaNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company manufactures solid oral dosage forms including beta and non-beta-lactam tablets and capsules.
- It produces oral liquids, external preparations, and dry powders for various therapeutic applications.
- Key products include Cefixime, Azithromycin, Sulmtmicilline, Aceclofenac, and Citicolin Sodium for diverse treatments.
Weaknesses
- The firm is engaged solely in the domestic business of manufacturing pharmaceutical products.
- It operates from Hyderabad, Telangana, which may limit immediate international market reach.
- The company went public on 30 June 2023, indicating a relatively recent market presence.
Opportunities
- Non-beta-lactam products treat general diseases like colds, flu, fever, and viral infections.
- External preparations offer ointments, creams, lotions, and gels designed for skin application.
- Expanding the range of beta-lactam medicines could address more bacterial infection treatments.
Threats
- Competition in the Indian pharmaceutical sector is intense and rapidly evolving.
- Regulatory changes in India could impact the manufacturing and distribution of pharmaceutical products.
- Fluctuations in raw material costs may affect the profitability of drug production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.